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Abstract Insulin-like growth factor-1 (IGF-1) isoforms
are expressed via alternative splicing. Expression of the
minor isoform IGF-1Eb [also known as mechano-growth
factor (MGF)] is responsive to cell stress. Since IGF-1
isoforms differ in their E-domain regions, we are interested
in determining the biological function of the MGF
E-domain. To do so, a synthetic peptide analog was used to
gain mechanistic insight into the actions of the E-domain.
Treatment of H9c2 cells indicated a rapid cellular uptake
mechanism that did not involve IGF-1 receptor activation
but resulted in a nuclear localization. Peptide treatment
inhibited the intrinsic apoptotic pathway in H9c2 cells
subjected to cell stress with sorbitol by preventing the
collapse of the mitochondrial membrane potential and
inhibition of caspase-3 activation. Therefore, we adminis-
tered the peptide at the time of myocardial infarction (MI)
in mice. At 2 weeks post-MI cardiac function, gene
expression and cell death were assayed. A significant
decline in both systolic and diastolic function was evident
in untreated mice based on PV loop analysis. Delivery of
the E-peptide ameliorated the decline in function and
resulted in significant preservation of cardiac contractility.
Associated with these changes were an inhibition of patho-
logic hypertrophy and significantly fewer apoptotic nuclei in
the viable myocardium of E-peptide-treated mice post-MI.
We conclude that administration of the MGF E-domain
peptide may provide a means of modulating local tissue IGF-
1 autocrine/paracrine actions to preserve cardiac function,
prevent cell death, and pathologic remodeling in the heart.
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Introduction
Ischemia that leads to myocardial infarction (MI) causes
cell death and necrosis in the ischemic region, an irre-
versible loss of muscle tissue and corresponding function.
In addition, cardiac myocytes in the viable nonischemic
regions undergo programmed cell death known as apop-
tosis [1]. The heart compensates for this loss of myocar-
dium by undergoing hypertrophic growth to maintain
cardiac output. During this remodeling phase, the necrotic
and apoptotic regions are replaced with fibrotic tissue
which alters ventricular compliance. This further exacer-
bates the loss of contractility leading to decompensation
and heart failure [2].
During these events, local neurohormonal peptides and
growth factors such as IGF-1 are produced by the myo-
cardium to mitigate the damage. Insulin-like growth factor
1 (IGF-1) has been extensively shown to inhibit apoptosis
in many cell types primarily by activating the IGF-1R/
PI3K/Akt pathway [3, 4]. Consistent with this notion are
data showing increased IGF-1 mRNA and protein
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expression in the border zone surrounding a MI in sheep
and rats [5, 6]. Myocytes isolated from various regions
(border zone and remote regions) show increased expres-
sion of IGF-1 supporting the view that IGF-1 expression
occurs within the cardiac myocytes [7]. A biphasic
response has been reported for IGF-1 mRNA expression in
the border zone, peaking initially at day 1, declining and
slowly rising by day 7 [5]. However, these studies did not
differentiate between the IGF-1 isoforms present, because
the hybridization probes or antibodies used only recognize
the conserved B, C, A, and D domains of the mature IGF-1
peptide (see Supplemental Data Fig. 1).
IGF-1 is expressed as a prepropeptide growth factor in
numerous tissues as different isoforms, but yet isoform
regulation and function are poorly understood. Alternate
splicing of the transcript gives rises to different classes of
transcript based on 50-end splicing, with different E-domain
regions based on 30-end splicing. With nomenclature based
on the different E-domains present in the propeptide form,
IGF-1Ea is the predominant isoform [8, 9]. In skeletal
muscle, alternate splicing leads to expression of minor
isoforms with different E-domain regions in response to
growth-promoting stimuli and following injury [10–13]. In
the rat heart, temporal regulation of the IGF-1 isoforms has
been recently reported following MI, but analysis of the
various isoform classes and cardiac myocyte expression
was not undertaken. The E-domains of all the isoforms
contain a conserved region (first 16 amino acids) derived
from exon 4, but diverge thereafter depending on the
combination of exons 4–5–6 translated. In rodents, a 52 bp
insert from part of exon 5 causes an open reading frame
shift and gives rise to the splice-variant IGF-1Eb. IGF-1Eb
has also been termed as mechano-growth factor (MGF),
due to its upregulation in response to mechanical pertur-
bation [14], and corresponds to the IGF-Ec isoform in
humans.
The function and significance of the E-domain regions
has become the focus of understanding differential IGF-1
isoform function. Over-expression of full-length cDNAs
encoding IGF-1Ea, IGF-Eb (MGF) prepropeptides com-
pared with the mature IGF-1 peptide (exons 3 and 4) results
in distinct patterns of gene expression suggesting that the
E-domains modulate IGF-1-mediated transcription [15].
Application of a synthetic peptide corresponding to the
unique 24 amino acid region of the MGF E-domain has
been shown to have distinct biological activity in C2C12
cells and skeletal muscle precursor cells [16, 17]. In rat,
H9c2 myocardial-like cells, the E-domain of MGF exerts
autonomous IGF-1 receptor-independent actions [18].
In vivo, intracoronary delivery of the MGF E-domain
peptide (E-pep) provides a cardioprotective effect inde-
pendently and synergistically with mature IGF-1 in an
ovine model of MI [19]. A reduction in infarct area and an
improvement in function 5-days post-MI was associated
with a reduction in caspase-3 activation in the peri-infarct
region of MGF E-domain-treated sheep. In addition, sys-
temic delivery of the MGF E-pep has also been shown to
produce a neuroprotective effect by preventing apoptosis in
a model of transient cerebral ischemia [20]. These data
indicate that the E-domain region of MGF may play a role
in preventing apoptosis and may provide insight to the
function of the MGF isoform.
Consequently, the aim of this study was to examine
subclass temporal expression of the IGF-1 isoforms in the
heart and cardiac myocytes following MI. In addition,
examine E-pep uptake, intracellular location and whether it
exerts anti-apoptotic actions in vitro. Finally, we wished
assess whether administration could reduce the severity of
MI, adverse remodeling and functional decline in mice
in vivo. Our data show that the MGF E-pep inhibits the
intrinsic apoptotic pathway through mechanisms aimed at
preventing the collapse of the mitochondrial resting
membrane potential and downstream activation of caspase-
3 in H9c2 myocardial-like cells in vitro. Administration of
a synthetic peptide at the time of MI prevents cell death in
the viable myocardium, preserves cardiac function, and
prevents pathologic cardiac hypertrophy. These data indi-
cate that MGF is a physiologically relevant isoform of IGF-
1 expressed at the time of injury in cardiac myocytes and
suggest that the E-domain region plays a role in mediating
the anti-apoptotic effects associated with IGF-1.
Materials and methods
The experiments were approved by the Institutional Ani-
mal Care and Use Committee in accordance with the NIH
guidelines.
E-domain peptides
A 24 amino acid peptide (YQPPSTNKNTKSQRRKGST-
FEEHK) corresponding to the unique C-terminal E-domain
region of the human MGF isoform (IGF-Ec) was synthe-
sized and purified to [90 % by HPLC (Genescript Corp,
NJ). The peptide was stabilized by amidating the C-ter-
minus and switching the arginines at positions 14 and 15 to
the D-stereoisomer. A scrambled peptide containing the
same amino acids in random order was used as a control
in vivo. Two additional peptides were also used for the
cell-based studies. A biologically inactive peptide created
by substituting the serine at position 18 to alanine (S18A)
and an N-terminus FITC-conjugated peptide for the cellu-
lar uptake analysis.
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H9c2 myoblasts
Rat H9c2 cells (American Type Culture Collection) were
maintained as subconfluent monolayers in growth medium
(Dulbecco’s modified eagle medium) supplemented with
10 % fetal bovine serum, plus 1 % penicillin, and strep-
tomycin at 37 C with 5 % CO2. 12 h prior to treatment,
the media was changed to DMEM plus 0.2 % BSA and
treatments initiated with a fresh change of media. Peptides
(50 ng/ml) were either used separately or in combination
with recombinant IGF-1 (rIGF-1), purchased from Sigma
(100 ng/ml).
Peptide uptake assay
H9c2 cells were seeded on a 96-well Optilux microtest
assay plate (BD Falcon) for 24 h. Media was changed to
DMEM ? 0.2 % BSA containing FITC-conjugated E-pep
and incubated for various times at 37 C. Cells were
washed several times in PBS (plus Ca2?Mg2?), lysed
directly in RIPA buffer (in mM: 150 NaCl, 1 % NP-40,
0.5 % deoxycholic acid, 0.1 % SDS, 50 Tris, pH 8.0) with
vigorous shaking for 20 min in the dark at RT. The fluo-
rescence signal was measured at 520 nm in a Bioteck
MicroPlate Reader (Synergy HT/190077).
Immunohistochemistry
Cells grown on coverslips were washed twice in PBS and
fixed in 10 % formalin for 10 min. Cells were further
washed in several changes of PBS before being perme-
abilized with PBS containing 0.2 % Tween 20 for 20 min.
Nonspecific binding was blocked with 3 % BSA, 2 % goat
serum in PBS containing 0.1 % Tween 20 for 30 min at
RT. Cells were incubated with a monoclonal antibody that
recognizes E-domain region (a kind gift from Dr. V.O.
Popov, Russian Academy of Sciences, Moscow, Russia) at
1:10,000 overnight at 4 C. Following, coverslips were
washed and then incubated with goat anti-mouse Alexa
Fluor 594 (invitrogen) secondary antibody diluted in PBS
containing 2 % BSA for 1 h at RT. Coverslips were
mounted in Vectoshield mounting medium with DAPI
(Vector Labs) and visualized with epifluorescence using an
Olympus IX81 inverted microscope equipped with a
Hamamatsu Orca cooled CCD digtial camera, 570–620 and
415 nm band pass filters, and 409 objective.
Mitochondrial membrane potential (DWm)
The DWm was assessed using ApoAlert Mitochondrial
Membrane Sensor Kit (Clontech). H9c2 cells were seeded
in a 96-well microtiter-plate and treated with 0.3 M sor-
bitol in DMEM (containing 0.2 % BSA and 1 % Pen/
Strep). At the end of treatment, cells were rinsed with
serum-free media and incubated in 5 lg/ml MitoSensor
Reagent for 30 min at 37 C plus 5 % CO2. Cells were
washed twice with PBS, resuspended in 100 ll PBS, and
analyzed in a microplate reader (Bioteck MicroPlate
Reader Synergy HT/190077). The DWm was assayed for
each sample using the ratio of 535 nm (FL1) versus
590 nm (FL2) fluorescence. Data are expressed as the ratio
of FL1/FL2 fluorescence.
Caspase activity assay
Cells were treated with 0.3 M sorbitol for 16 h. Caspase 3
activity was assayed using Caspase Colorimetric Substrate/
Inhibitor Quantipak (Biomol International, LP) following
the manufacturer’s instructions. Cells were incubated in
lysis buffer (in mM: 50 HEPES, 0.1 % CHAPS, 1 DTT, 0.1
EDTA, pH 7.4) on ice for 5 min and then centrifuged at
10,0009g for 10 min at 4 C. Supernatants (10 ll) were
loaded on a 96-well microtiter-plate containing 80 ll of
assay buffer (in mM: 50 HEPES, 100 NaCl, 0.1 % CHAPS,
10 DTT, 1 EDTA, 10 % Glycerol, pH 7.4). The reaction
was started by the addition of Ac-DEVD-pNA (10 ll).
OD405nm was measured in 5 min intervals for 2 h in a
microplate reader (Bioteck MicroPlate Reader Synergy
HT/190077). To measure caspase-8 and -9 activities, spe-
cific substrates IETD–pNA and LEHD–pNA were used,
respectively, to initiate the reaction.
MI and peptide treatment
Male B6/SJL 3-month old mice were anesthetized with 3 %
isoflurane inhaled in a closed chamber and Etomidate
(10 mg/kg, i.p.). Mice were intubated and connected to a
rodent ventilator and additional anesthesia was regulated by
the delivery of 1.5 % isoflurane through a vaporizer with
100 % oxygen. The left anterior descending coronary artery
was ligated with 8-0 silk suture 1–2 mm below the left
atrium, as previously published [21]. Peptides were admin-
istered via micro-osmotic pumps (Alzet, Model 1007D,
Durect Corp, CA) implanted subcutaneously, slightly pos-
terior to the scapula under general anesthesia. Peptides were
dissolved in 25 % mouse serum in 0.9 % NaCl at concen-
trations sufficient to allow an infusion rate of 4.5 mg/Kg/
day. Untreated control mice and infarcted mice received
vehicle via micro-osmotic pump. Pumps were implanted
12 h before coronary artery ligation to ensure appropriate
dose, and replaced after 7 days for 2 week treatments.
Myocyte isolation
While under anesthesia, mice were heparinized (5,000 units/
kg), and the heart was quickly removed and placed in a
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ice-cold nominal Ca2?-free control solution (in mM: NaCl
133.5, KCl 4, NaH2PO4 1.2, MgSO4 1.2, HEPES 10, and
glucose 11). The aorta was cannulated and the heart mounted
on a Langendorff apparatus and perfused at constant tem-
perature 37 C and flow of 3 ml/min for 4 min with Ca2?-
free control solution containing (in mM: 113 NaCl, 4.7 KCl,
0.6 KH2PO4, 0.6 Na2HPO4, 1.2 MgSO47H2O, 12 NaHCO3,
10 HEPES, 30 taurine, 0.032 phenol red, 10 butanedione
monoxime (BDM), and 5.5 glucose) followed by an identical
buffer containing additional enzymes (0.25 mg/ml Blend-
zyme I (Roche), 0.14 mg/ml trypsin, and 12.5 lM CaCl2) for
8 min. Hearts were removed, minced in digestion buffer,
then pipetted for 1–2 min until the cells were completely
dissociated. The cell suspension was rinsed in stop buffer
(control buffer plus 5 % of bovine serum albumin) to inac-
tivate the enzymes.
Western blotting
Freshly isolated adult cardiac myocytes were lysed in buffer
(in mM: 20 Tris–HCl (pH 7.4), 2 EDTA, 10 EGTA, 320
sucrose, 0.3 PMSF, 20 lg/ml leupeptin, and 10 b-mercap-
toethanol). Protein quantification was determined by the DC
Protein Assay (Bio-Rad). Samples diluted 1:2 with Laemmli
sample buffer and heated (68 C) for 5 min. Proteins were
separated on a 10–20 % gradient gel. H9c2 cells were lysed
in RIPA buffer, containing Protease Inhibitor Cocktail Set I
(Calbiochem) and Phosphatase Inhibitor Cocktail 1 (Sigma-
Aldrich), prior to SDS-PAGE on 12 % acrylamide gels
before transferring to nitrocellulose. Membranes were
incubated in blocking buffer consisting 5 % nonfat dry milk
in TBS (in mM: 20 Tris–HCl, 137 NaCl, pH 7.6) for 1 h.
Affinity-purified antibodies against phospho-IGF-1 receptor
(Tyr980 and Tyr1131) phospho-Akt (Ser473), actin (cell sig-
naling), and the E-domain monoclonal antibody were used at
1:1,000 overnight at 4 C. After washing membranes in
TBS-T, secondary antibody (goat anti-rabbit diluted 1:1,000
in blocking buffer) was added for 1 h at RT. Immunoreactive
bands were detected with SuperSignal West Pico Chemilu-
minescent Substrate (Pierce) and visualized using autora-
diographic film.
Cardiac function
A 1.4 French pressure–conductance catheter (SPR-839,
Millar Instruments, Houston, TX, USA) was inserted ret-
rograde into the left ventricle and pressure–volume loops
recorded (ARIA Pressure Volume Conductance System,
Millar Instruments) in anesthetized mice as described
[21, 22].
Quantitative RT-PCR
Total RNA was extracted from the apex of the heart with
TRIzol (Invitrogen), and used in a one-step RT-PCR reac-
tion with the SYBR Green RNA Amplification kit (Roche
Molecular Biochemical, IN) in the LightCycler thermocy-
cler (Roche Diagnostics). The reaction conditions for the
reverse transcriptase were 55 C for 15 min, a denaturing
step at 95 C for 30 s, followed by four-step PCR amplifi-
cation for 40-cycles. The second derivative maximum (log
linear phase) for each amplification curve was plotted
against a standard curve to calculate the amount of product.
Samples from mouse hearts were normalized against
GAPDH and H9c2 cells normalized against ribosomal pro-
tein L7, as previously described [21, 22]. Primers were
designed using GenBank reference sequences and the
primer design tool Primer 3 (http://frodo.wi.mit.edu/cgi-bin/
primer3/primer3_www.cgi). Primer sequences were run against
the BLAST database and used for melting curve analysis
prior to PCR amplification to ensure single gene specific
product amplification.
Gene Forward primer Reverse primer Genebank accession
number
IGF-1Ea GCTTGCTCACCTTCACCAGC AAATGTACTTCCTTCTGAGTCT NM_001111275
IGF-1Eb (MGF) GCTTGCTCACCTTCACCAGC AAATGTACTTCCTTTCCTTCTC NM_010512
Class I-MGF ATGGGGAAAATCAGCAGCC CACCATCATGTCGTCCCACACCTCTT NM_010512
Class II-MGF ATGACCGCACCTGCAATAAAG CACCATCATGTCGTCCCACACCTCTT NM_001111274
a-Myosin heavy chain AAGGTGAAGGCCTACAAGCG TTTCTGCTGGACAGGTTATTCC M76601
b-Myosin heavy chain AAGGTGAAGGCCTACAAGCG TTCTGCTTCCACCTAAAGGGC M74752
Atrial natriuretic factor TGGAGGAGAAGATGCCGGTA CGAAGCAGCTGGATCTTCGTAG K02781




Rat IGF-1 Eb (MGF) GCTTGCTCACCTTCACCAGC AAATGTACTTCCTTTCCTTCTC NM_001082478
RPL7 GAAGCTCATCTATGAGAAGGC CAGACGGAGCAGCTGCAGCAC NM_001100534
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In situ cell death
Hearts were removed, fixed in 10 % buffered formalin and
5 lm sections cut from paraffin-embedded blocks. TUNEL
staining was conducted using the In situ Cell Death Detection
Kit TMR Red (Roche), according to the manufacture’s
instructions with slight modifications. Sections were deparaff-
inized and incubated with Retrievagen A buffer (BD Pharm-
ingen) at 86 C for 12 min and then cooled to RT for 20 min.
Sections were washed with PBS for 15 min and the enzyme
mix applied for 10 min at 37 C. Slides were washed and
mounted with DAPI. Three digital images from the infarct
border zone and viable myocardium were taken and analyzed.
Digital visualization, analysis, and calculations were performed
using Volocity software (Improvision). The numbers of nuclei
in each field were highlighted by selecting a pixel in the middle
of the nucleus and drawing the region of interest outwards
(Drawing Region of Interest Tool) until the maximum threshold
was reached. Tolerance was set at 25 % similar to the picked
voxel for all objects and objects smaller than 3 lm were
excluded from final analysis. Colocalization of signal within the
same voxel location in each channel was used to determine the
number of total and apoptotic nuclei in the same image field.
Data are expressed as percent apoptotic nuclei.
Infarct quantification
Duplicate 1 mm mid-LV sections were cut and incubated
with 1 % triphenyl tetrazolium chloride (TTC) for 20 min
at 37 C. The infarct size was determined by planimetry of
the infarct zone (white) and expressed as a percent of the
total LV area on digital images at 109 magnification
(Advanced SPOT Diagnostic Instruments) [21].
Statistics
Data are expressed as means ± standard error (SE). The
difference in the mean was tested using either Student’s
t test or ANOVA followed by Newman–Keuls post hoc
analysis, where appropriate. Cardiac function data were
analyzed using two-way ANOVA to test the influence of
two independent variables: infarct and treatment. All pair-
wise multiple comparisons were performed using the Holm-
Sidak method to test for statistical significance (P \ 0.05).
Results
The MGF isoform is expressed in response to cell stress
in vitro
Studies have shown that sorbitol treatment induces osmotic
shock, oxidative, metabolic stress, mitochondrial calcium
overload which all lead to apoptosis in H9c2 rat cardio-
myoblasts and cultured cardiac myocytes [23–29]. To
ascertain whether the endogenous MGF isoform is
expressed in H9c2 cells in response to cell stress, cells were
treated with 0.3 M sorbitol. MGF isoform expression sig-
nificantly increased by 24 h suggesting that the IGF-1
isoform splicing was responsive to cell stress in H9c2 cells.
Immunohistochemical analysis using an E-domain-specific
antibody revealed a perinuclear and nuclear localization of
the MGF E-domain (Fig. 1a, b).
MGF E-domain is taken up by the cell without
IGF-1 receptor activation
Given several biological processes have been reported to
be regulated by the 24 a.a. peptide derived from the
E-domain region of MGF, we examined cellular uptake
using a FITC-labeled E-pep. Treatment resulted in a dose-
dependent increase in cellular fluorescence, which peaked
at 10 min (Fig. 1c). Competition of FITC-labeled E-pep
with increasing concentrations of unlabeled peptide resul-
ted in a significant decrease in fluorescence with a 4-fold
concentration of unlabeled E-pep (Fig. 1d). To rule out the
possibility of nonspecific electrostatic interaction, cells
were treated with FITC alone and at 4 C. Lowering the
temperature to 4 C solidifies the plasma membrane and
prevents endocytosis or receptor internalization. FITC
alone produced a low level of fluorescence, whereas
incubation at 4 C significantly decreased the amount of
FITC-labeled peptide able to enter the cell (Fig. 1d).
Staining with an E-domain-specific antibody revealed
nuclear accumulation of the peptide within 15 min, which
persisted for up to 24 h (data not shown) (Fig. 1e).
Since MGF is a splice variant of IGF-1, the impact of
E-pep treatment on IGF-1R/Akt signaling was examined.
Treatment with the E-pep did not activate the IGF-1
receptor as measured by phosphorylations at Tyr980
(Fig. 1f) and Tyr1131 (data not shown) whereas IGF-1 alone
did. Application of the propeptide form (IGF-1 ? E-
domain) showed no apparent difference in receptor phos-
phorylation compared with IGF-1 alone. A similar effect
was also noted with respect to Akt phosphorylation at
serine 473 (Fig. 1f).
MGF E-domain inhibits the intrinsic apoptotic pathway
in vitro
Previous data from sheep treated with the E-pep following
MI suggested that the E-pep may exert anti-apoptotic
actions [19]. H9c2 cells were treated with sorbitol and the
mitochondrial membrane potential (DWm) analyzed. A
progressive increase in the fluorescence ratio with time of
sorbitol treatment indicated a collapse of the DWm was
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prevented with E-pep treatment (Fig. 2a). The collapse of
the DWm signals the onset of the apoptotic cascade due to
release of cytochrome c into the cytoplasm, which activates
caspase-9. Caspase-9 activity was significantly elevated in
response to sorbitol but inhibited with E-pep treatment
(Supplementary Data Fig. 2a). E-pep treatment of the
extrinsic pathway via caspase 8 showed no effect, indi-
cating an inhibition of the intrinsic apoptotic pathway
(Supplementary Data Fig. 2b). Since caspase-3 is a termi-
nal enzyme in the apoptosis cascade and receives input
from upstream caspases, we assessed its activation as an
index of cell fate. Sorbitol-induced caspase-3 activation
which was prevented with E-pep treatment. This effect
appeared to be more potent than IGF-1 treatment alone and
when added in combination with IGF-1 did not provide an
additive effect. These data suggest that the E-domain may
engage the IGF-1 cell survival pathway with different
spatial–temporal dynamics or different survival pathways
to prevent caspase-3 activity (Fig. 2b). To define whether
the actions of the E-pep were specific, a peptide in which
the serine at position 18 was substituted to alanine (S18A)
was used. Substitution of the terminal serine rendered the
E-pep biologically inactive as indicated by an inability to
inhibit caspase-3 activity.
The MGF isoform is induced immediately following
MI
To characterize the expression of the IGF-1 isoforms
expressed in the mouse heart following MI, isoform spe-
cific primers were used. There was a significant increase in
IGF-1Eb (MGF) expression 24 h post-MI, while expres-
sion of IGF-1Ea did not change (Fig. 3a, b). Analysis up to
2 week post-MI showed IGF-1Ea was significantly
increased 7 and 14 days post-MI, while MGF expression
declined to baseline levels (Fig. 3b, c). Finally, analysis of
the 50-splice variants revealed that the class-1 MGF tran-
script predominates and is significantly increased 24 h
post-MI (Fig. 3d).
To determine whether MGF protein expression was
increased, the MGF E-domain specific antibody was used
to probe isolated myocyte protein extracts (Fig. 3e). In
addition, protein from the atria of a previously character-
ized transgenic mouse model that develops heart failure
was used as a biological source for comparison [22]. The
left atrial enlargement noted in this model is due to the
development of a thrombus but expresses high levels of
MGF transcript (data not shown). Multiple bands were
identified in both 24 h post-MI myocyte and left atrial
protein extracts, likely representing the prepropeptide and
propeptide forms of MGF. The presence of a faster
migrating band below 15 kDa in protein extracts similar to
the synthetic E-pep, suggests that the E-domain region of
MGF is cleaved in myocytes following MI.
Fig. 2 MGF E-peptide exerts anti-apoptotic actions in H9c2 cells.
a Mitochondrial membrane potential in response to 0.3 M sorbitol
and MGF E-domain peptide treatment for various times (*P \ 0.05
vs. sorbitol ? MGF E-domain). b Caspase-3 activity in response to
sorbitol treatment (12 h), with MGF E-domain peptide and MGF
E-domain peptide containing an amino acid substitution (S/A),
(*P \ 0.05 vs. control, #P \ 0.05 vs. IGF-1, n = 5)
Fig. 1 a Endogenous MGF isoform mRNA expression following
exposure to 0.3 M sorbitol in H9c2 cells (*P \ 0.05 vs. control,
n = 3). b Immunostaining with MGF E-domain-specific antibody in
H9c2 cells following 24 h sorbitol treatment (Red is E-domain
specific antibody, blue is DAPI). c Quantification of FITC-conjugated
MGF E-domain peptide uptake in H9c2 cells with various concen-
trations. d Competition assay with excess unlabeled MGF E-domain
peptide with 10 min incubation, FITC alone and incubation at 4 C
(*P \ 0.05 vs. control, n = 5). e Immunostaining of cells treated with
the E-domain peptide (30 nM) for 15 min with an MGF E-domain-
specific antibody and counter stained with DAPI. f Immunoblot of
H9c2 cell lysates treated with MGF E-domain peptide, IGF-1 or MGF
E-domain peptide ? IGF-1 for 15 min. Anti-pIGF-1R (Tyr980), anti-
pAkt (Ser473) to examine IGF-1 receptor and pathway activation.
Anti-actin shows equal loading among samples. (Color figure online)
b
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MGF E-domain treatment preserves contractility
and cardiovascular function post-MI
To examine the salutary actions of E-pep treatment in vivo, we
delivered the stabilized peptide to infarcted mice. Pressure–
volume loop analysis was performed to assess cardiovascular
function in mice treated with the E-pep, or a scrambled peptide
(SCR-pep), at 2 week post-MI. Hemodynamic variables
measured in all control groups (control, control ? SCR-pep,
control ? E-pep) showed no differences after 2 week treat-
ment. Analysis of MI ? SCR-pep showed no differences
compared with MI alone, whereas MI ? E-pep treatment did
show significant differences (Table 1).
Overall, there was a significant decline in cardiac function
in both MI- and MI ? SCR-pep-treated mice compared with
controls. This was reflected in the increased end systolic and
end diastolic volumes, decreased systolic function (ESP, SV,
CO, and SW) and increased diastolic dysfunction (EDP, Tau).
Treatment with the E-pep resulted in a number of hemody-
namic variables being either preserved or attenuated, despite
similar signs of early dilation, based on the volume intercept
(Vint). The pressures developed (MAP, ESP, and EDP) were
either similar to those measured in control mice or attenuated.
While other functional parameters declined, particularly with
respect to volumes (SV and CO), they did so to a lesser extent
than the MI and MI ? SCR-pep-treated groups (Table 1). In
addition, measurements of load-dependent cardiac contrac-
tility or work (stroke work, dP/dtmax, dP/dtmin, PAMP) were
statistically improved in MI ? E-pep-treated mice compared
with MI and MI ? SCR-pep-treated mice (Table 1).
Measures of cardiac contractility obtained during tho-
racic vena cava occlusion, showed the end-systolic pres-
sure volume relationship (ESPVR) was significantly
depressed in MI mice but to a lesser extent in MI ? E-pep
mice (Fig. 4a). The end-diastolic pressure volume rela-
tionship (EDPVR) was elevated in MI and MI ? SCR-pep
Fig. 3 Expression and quantification of IGF-1 isoform expression in
the mouse heart following MI. a, b Quantification of the 30-splice
variants using isoform specific primers at various times post-MI
(*P \ 0.05, n = 4). c Analysis of 50-splice variants of the MGF
transcript (rodent IGF-1Eb), with class/isoform specific primers 24 h
post-MI (*P \ 0.05). d Western blot of myocyte protein extracts
isolated from control and 24 h post-MI hearts (duplicate samples).
Protein extracts from the atria of a PKCe transgenic mouse run as
positive controls (arrow indicates migration of fragment \15 kDa).
The synthetic E-domain peptide was also run under similar conditions
and probed with an MGF E-domain-specific antibody
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mice but did not differ from control in MI ? E-pep mice
(Fig. 4b). Preload recruitable stroke work (PRSW), reveals
changes in systolic function independent of chamber
geometry, was preserved in MI ? E-pep-treated mice
(Fig. 4c). Likewise, maximal dP/dt versus maximal EDV
(dP/dtmax versus EDVmax) was also preserved in the
MI ? E-pep-treated mice (Fig. 4d). Time-varying elastance
(Emax) indicates the temporal course of the chamber stiff-
ness, decreased significantly in post-MI mice but was
attenuated in MI ? E-pep-treated mice (Fig. 4e). Finally,
assessment of global cardiovascular function expressed as
the vascular–ventricular (A-V) coupling ratio (Ea/Es),
revealed significant differences. The Ea/Es ratio was signif-
icantly increased in MI and MI ? SCR-pep mice (Table 1).
An increase in the Ea/Es ratio suggests that an increase in
vascular resistance is occurring along with a decrease in
mechanical efficiency of the ventricle. However, the Ea/Es
ratio was significantly lower in MI ? E-pep mice and plot-
ted against cardiac contractile efficiency indicates that an
improvement in mechanical efficiency of the ventricle
occurred independently of vascular changes (Fig. 4f).
MGF E-domain treatment prevents cardiac hypertrophy
post-MI
Analysis of heart weight and molecular markers was used
to assess the extent of cardiac hypertrophy. A significant
increase in the heart weight to body weight ratio (HW/BW)
in MI and MI ? SCR-pep mice was inhibited in MI ?
E-pep mice (Fig. 5a). Analysis of myosin heavy chain
isoform expression showed preserved a-MHC isoform
expression in MI ? E-pep-treated hearts compared with
MI and MI ? SCR-pep-treated hearts. Conversely, there
was a reciprocal increase in b-MHC isoform expression in
MI and MI ? SCR-pep hearts, which was suppressed in
MI ? E-pep-treated hearts (Fig. 5b, c). A significant
increase in ANF expression evident in MI and MI ? SCR-
pep was prevented in MI ? E-pep-treated hearts (Fig. 5d).
Analysis of the matrix metalloproteinases implicated in
extracellular matrix remodeling post-MI showed that
MMP-2 mRNA expression was significantly increased in
MI and MI ? SCR-pep-treated hearts but not MI ? E-pep-
treated hearts (Fig. 5e).
Table 1 Cardiac function in mice at 2 week post-MI with and without MGF E-peptide treatment
Group
parameter




2 week MI 2 week MI ?
SCR-peptide
2 week MI ?
E-peptide
HR 594 ± 20 546 ± 25 526 ± 24 555 ± 17 565 ± 27 530 ± 16
MAP 80 ± 2.5 71 ± 1.9 74 ± 1.3 61 ± 5* 66 ± 4.0* 76 ± 3.6
EDV 46 ± 1.0 47 ± 4.0 50 ± 3.0 66 ± 3.1* 69 ± 3.0* 68 ± 2.4*
ESV 25 ± 0.7 24 ± 0.8 27.5 ± 1.0 53 ± 3.3* 58 ± 2.5* 55 ± 3.5*
Vint 22.4 ± 1.4 21.2 ± 0.8 24 ± 1.3 38.9 ± 4* 49 ± 2.7* 39.6 ± 3.5*
ESP 102 ± 2.2 102 ± 8.8 93 ± 2.0 77 ± 3.1* 79 ± 3.0* 92 ± 3.5
EDP 6.8 ± 0.7 7.0 ± 1.0 6.7 ± 0.8 9.7 ± 1.5* 9.7 ± 1.7* 8.2 ± 1.4*
SV 20.8 ± 0.7 22.6 ± 2.7 22.4 ± 1.0 12.2 ± 1.7* 12.9 ± 0.7* 15.1 ± 1.4*
CO 12,138 ± 972 11,879 ± 1,835 11,891 ± 742 6,987 ± 871* 6,850 ± 650* 7,938 ± 933*
SW 1,645 ± 60 1,749 ± 199 1,645 ± 170 645 ± 72* 713 ± 77* 1,236 ± 154*,
dP/dtmax 11,321 ± 560 10,053 ± 346 8,957 ± 337 5,692 ± 311* 6,085 ± 409* 10,357 ± 240

dP/dtmin -10,344 ± 617 -8,704 ± 237 -8,632 ± 235 -5,562 ± 546* -5,988 ± 418* -8,918 ± 285

Tau-G 8.3 ± 0.6 8.7 ± 1.1 7.3 ± 0.3 15.4 ± 3.5* 10.3 ± 0.8* 9.7 ± 0.5*
PAMP 60.6 ± 7.6 55.6 ± 5.3 48 5 ± 6.1 9.6 ± 1.2* 8.6 ± 1.0* 23.0 ± 2.0*
TPR 6.8 ± 0.6 6.3 ± 0.7 6.4 ± 0.5 10.2 ± 1.6* 10.4 ± 1.3* 9.3 ± 1.0*
Ea 4.6 ± 0.23 4.6 ± 0.8 4.5 ± 0.5 6.6 ± 0.6* 7.7 ± 0.7* 7.5 ± 0.6*
Ea/Es 0.20 ± 0.01 0.23 ± 0.04 0.28 ± 0.04 0.84 ± 0.06* 0.71 ± 0.11* 0.60 ± .0.04*
,
Pressure–volume loop measurements collected in the closed chest configuration
HR Heart rate (beats per minute), MAP mean arterial pressure (mmHg), EDV end diastolic volume (ll), ESV end systolic volume (ll), Vint
volume intercept (ll), ESP end-systolic pressure (mmHg), EDP end-diastolic pressure (mmHg), SV stroke volume (ll), CO cardiac output (ll/
min), SW stroke work (mmHg/ll), dP/dtmax maximum first derivative of change in systolic pressure with respect to time (mmHg/s), dP/dtmin
maximum first derivative of change in diastolic pressure with respect to time (mmHg/s), Tau-Glantz-time constant of fall in ventricular pressure
by Glantz method (ms), PAMP preload adjusted maximal power (mWatts/ml2), TPR total peripheral resistance (mmHg/ml/min), Ea/Es vascular-
to-ventricular coupling
* P \ 0.05 versus control;  P \ 0.05 versus 2 week MI (n = 6 per group)
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Fig. 4 Cardiac contractility based on P–V loop measurements
collected during transient occlusion of thoracic vena cava in 2 week
post-MI mice with and without MGF E-peptide treatment. a ESPVR-
end systolic pressure volume relationship. b EDPVR-end diastolic
pressure volume relationship. c PRSW-preload recruitable stroke
work. d dP/dtmax versus EDVmax-maximal dP/dt versus maximal end
diastolic volume. e Emax-time-varying maximal elastance. f The
relationship between A–V coupling ratio (Ea/Es) and cardiac
contractility efficiency (CCE) in all 2 week post-MI mice
(*P \ 0.05 vs. control and P \ 0.05 vs. 2 week MI, n = 6)
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Fig. 5 Quantification of cardiac mass and gene expression in 2 week
post-MI mice with and without MGF E-peptide treatment. a Heart
weight to body weight ratios. b a-myosin heavy chain isoform
expression. c b-myosin heavy chain isoform expression. d ANF
expression. e Metalloproteinase expression MMP2 (*P \ 0.05,
#P \ 0.01 vs. control, n = 5)
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MGF E-domain inhibits cell death in the viable
myocardium in vivo
The extent of cardiac myocyte cell death was assessed using
TUNEL staining in sections cut from MI and MI ? E-pep-
treated hearts. The numbers of TUNEL positive nuclei were
analyzed in the border zone of the infarct and viable myo-
cardium. The data show that while the numbers of apoptotic
nuclei tended to be lower in the border zone of MI ?
E-pep-treated hearts, there was a significant difference in
the viable region compared with MI alone (Fig. 6a). Anal-
ysis of infarct size showed that infarct size at 2 week was
not different between the groups (Fig. 6b). These data
suggest that E-peptide treatment may exert a protective
effect on the cardiac myocytes in the viable myocardium
that would otherwise undergo cell death as a result of the
increased mechanical strain following MI.
Discussion
Myocyte death due to ischemia results in a loss of myocar-
dium, a functional deficit and mechanical overload. In
addition, apoptosis also contributes to myocyte drop-out in
the remote regions of the myocardium in which there is
increased mechanical strain. In order to compensate the
remaining cardiac myocytes undergo hypertrophy as a
means to normalize wall stress and generate the force
required to maintain cardiac output. It has been postulated
that apoptosis and hypertrophy that follow mechanical
overload are related events, with hypertrophy being initiated
by a wave of apoptosis [30]. During these events, local
neurohormonal peptides and growth factors such as IGF-1
are produced by the myocardium to mitigate damage.
However, these cardioprotective responses are often insuf-
ficient to avert the progression of deleterious events but if
enhanced could serve as a means of therapeutic intervention.
As such, we demonstrate that delivery of a peptide derived
from the propeptide form of MGF, an IGF-1 isoform
expressed acutely in the heart at time of injury, preserves
cardiac function, and prevents cell death and pathologic
hypertrophy in post-MI mice. We also demonstrate that the
E-domain region prevents apoptosis by inhibiting the
intrinsic apoptotic pathway in vitro, correlating this with the
anti-apoptotic outcome and preservation of cardiac function
with delivery during MI in vivo.
There is strong evidence regarding the importance of IGF-
1 as a regulator of myocardial growth and a protector against
myocardial cell death in vitro [31, 32]. Also, improvement in
cardiac function has been reported following growth hor-
mone administration as a means of increasing systemic IGF-
1 levels in animal models [33, 34]. However, these favorable
results have not translated well in clinical trials, which do not
demonstrate significant prolonged effects of IGF-1 or growth
hormone administration [35, 36]. This may not be too sur-
prising since there is scant evidence supporting increased
secretion of growth hormone or elevated systemic IGF-1
following MI. In fact, data to the contrary exists showing
lower-systemic levels of IGF-1 in patients with acute MI
[37]. In addition, the limited bioavailability of IGF-1 once
bound to its binding proteins in the circulation is a major
therapeutic hurdle. Moreover, these studies speak to the
difficulty of defining the effects of IGF-1 produced by the
tissue from those of systemic IGF-1 and the assumption that
administration of the mature peptide reflects all the biologic
actions of IGF-1, when it is produced as a prepropeptide
within the physiologic environment.
To address some of these limitations in the context of
the heart, cardiac over-expression studies have demon-
strated the effects of local IGF-1 and have shown anti-
apoptotic actions in myocytes following MI [38]. These
Fig. 6 Quantification of cell death in different regions and infarct
size in 2 week post-MI mice. a The percentage of TUNEL positive
nuclei in the border zone and viable myocardium 2 weeks post-MI
with E-domain peptide treatment (*P \ 0.05 vs. 2 week MI).
b Infarct size in MI and MI ? E-peptide-treated mice (n = 5)
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salutary effects were attributed to local IGF-1 produced by
the muscle even though the liver cDNA used (human class-
2 IGF-1Eb) could not be spliced to produce muscle iso-
forms and resulted in elevated systemic levels of IGF-1
[38]. Likewise, over-expression of the predominant IGF-
1Ea isoform also provided protective effects through a
combination of anti-inflammatory and anti-apoptotic
actions post-MI [39]. However, neither over-expression
study addressed the actions of the E-domain independently
of the mature peptide. Thus, elucidating which IGF-1 iso-
form may function in the role of a protector/growth pro-
moter in the heart is important since developing a means to
manipulate the IGF-1 system could be advantageous. In
this regard, targeting MGF (human IGF-1Ec or rodent IGF-
1Eb) as a physiologically relevant isoform is appealing.
Data presented here and in other studies corroborate, the
MGF isoform is acutely up-regulated with different tem-
poral dynamics than the IGF-1Ea isoform following injury
[12, 18]. Furthermore, since the E-domain of MGF appears
to be cleaved in injured tissues this raises the possibility
that the E-domain may have distinct or synergistic actions
to the mature peptide of IGF-1. Supporting this further are
an increasing number of studies involving neurological and
cardiac models of injury in which delivery of the E-pep of
MGF has now been shown to be beneficial [19, 20, 40].
The nature of the molecular mechanism by which the
E-domain exerts its effects or influences the actions of IGF-
1 still remains to be defined. Our data indicate that a
nuclear localization of the endogenous protein and exoge-
nous peptide may be linked to its primary site of action.
Also, our data show that the E-pep does not activate the
IGF-1 receptor and downstream effector Akt, which form
part of the canonical IGF-1 pathway in H9c2 cells. Similar
effects have been reported with respect to the E-pep
nuclear actions and signaling. Incubation of skeletal muscle
myoblasts with an IGF-1 receptor antibody did not block
the biological actions of the E-pep in the context of pro-
liferation and migration [17]. Moreover, in neurons and
neuronal cell lines subjected to neurotoxic stress, the E-pep
did not activate Akt, but selectively increased the expres-
sion of heme oxygenase-1 via nuclear localization of Nrf2
which appears to be mediated by PKCepsilon [40, 41]. In
H9c2 cells, the MGF E-pep reportedly activates the p44/42
MAPK pathway independently of the canonical IGF-1
pathway [18]. Collectively, these data and ours suggest that
the E-pep appears to be able to enter the cell by a yet to be
defined mechanism, but results in divergent pathway
recruitment that converges on transcriptional regulation as
a means of inhibiting cell death.
In addition to the anti-apoptotic effects of IGF-1, the
effects on cardiac inotropy and physiological adaptation are
well known. In rodent models infusion of both IGF-1 and
growth hormone induces cardiac hypertrophy without
activation of the fetal gene program and produces a positive
inotropic effect [42]. These salutary effects were also dem-
onstrated by using a cardiac-specific IGF-1 over-expression
mouse to rescue a dilated phenotype via restoration of cal-
cium dynamics in a model of contractile dysfunction [43].
However, our hemodynamic data do not indicate inotropic
actions as a means of explaining the functional preservation
observed since control mice treated with the E-peptide did
not exhibit increased contractility compared with untreated
mice. Rather, our data suggest that the functional response
noted in the post-MI mice is likely due to a preservation of
contractile function, which could be due to an inhibition of
the mitochondrial-mediated cell death pathway of myocytes
in the viable myocardium or could arise from preservation of
the adult rodent myosin heavy chain isoform (aMHC)
expression in those cells. Preventing switching of the aMHC
isoform expression to the bMHC often associated with
pathologic remodeling could provide a novel means of per-
severing contractile force. However, within the context of
this study in which the peptide was delivered at the time of
MI, the causality of this function improvement is difficult to
define and would require further studies of delivery over
different time points.
The fate of the endogenous E-domain upon cleavage in
the cardiac myocyte is a critical issue. Once designated to the
secretory pathway, IGF-1 is cleaved by members of the
proprotein convertase (PC) family, of which furin is ubiq-
uitous and can act as a cellular endoprotease or extracellular
protease. It has been demonstrated that IGF-1 propeptide
processing in 293 cells by furin occurs at the Arg68–XX–
Arg71 site between the D- and E-domains to yield the 70
amino acid IGF-1 peptide [44]. However, additional cleav-
age motifs exist within the E-domain regions of the different
isoforms, so development of a stabilized peptide analog was
necessary [45]. Consequently, our cellular uptake data
indicate that exogenous application of the E-pep utilizes a
physiological cell entry mechanism to account for its intra-
cellular actions. The exact mechanism by which this occurs
is not known but may involve an interaction with the IGF-1
receptor without activation, a unique receptor-mediated
pathway or endocytosis. Whether this reflects the fate and
actions of the endogenous MGF E-domain region upon
cleavage are still to be determined.
We acknowledge the limitations of this study extend to
use of the permanent coronary ligation model, the time of
peptide delivery, and the dose and duration of peptide
treatment. Nevertheless, our data support the notion that
the E-domain regions of IGF-1 isoforms have biological
action and provide insight into the function of the MGF
E-domain. Furthermore, our data highlight that the regu-
lation of IGF-1 and its actions are more complex than those
detailed at the level of the receptor. Consequently, recent
interest in defining isoform function has centered on the
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E-domains since they vary between the different isoforms.
Given that tissue stress/injury engages IGF-1 splicing, it is
reasonable to postulate that this may underlie the physio-
logic basis for isoform function. Thus, our data support the
concept that modulating IGF-1 isoform function via the
E-domain may provide a feasible strategy to lessen overall
tissue damage, preserve contractile function, and reduce
pathologic remodeling in the heart.
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